Kronos Bio, Inc. Common Stock
KRON XS2338070365
Kronos Bio Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of small molecule therapeutics to address deregulated transcription, a hallmark of cancer and autoimmune diseases.
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
Person | Price | Shares | Total | Published | Completed |
---|---|---|---|---|---|
Knobelman Deborah CEO |
0.87 USD |
24,838 Sold |
21,554 USD |
05/06/2025 | 05/06/2025 |
Knobelman Deborah CEO |
0.87 USD |
24,838 Sold |
21,554 USD |
05/06/2025 | 05/06/2025 |
Bischofberger Norbert W CEO |
1.25 USD |
204,670 Bought |
254,957 USD |
27/06/2024 | 28/06/2024 |
Bischofberger Norbert W CEO |
1.17 USD |
410,848 Bought |
478,843 USD |
27/06/2024 | 27/06/2024 |
Bischofberger Norbert W CEO |
1.24 USD |
881,913 Bought |
1,096,041 USD |
10/06/2024 | 12/06/2024 |
Bischofberger Norbert W CEO |
1.09 USD |
744,308 Bought |
814,571 USD |
10/06/2024 | 11/06/2024 |
Bischofberger Norbert W CEO |
0.88 USD |
1,378,901 Bought |
1,208,469 USD |
10/06/2024 | 10/06/2024 |
Frisbee Allison VP |
1.05 USD |
12,105 Sold |
12,757 USD |
21/02/2024 | 21/02/2024 |
Olek Elizabeth A VP |
1.05 USD |
7,368 Sold |
7,765 USD |
21/02/2024 | 21/02/2024 |
Lin Charles Y VP |
1.05 USD |
12,036 Sold |
12,685 USD |
21/02/2024 | 21/02/2024 |